Oncology Venture (OV) is a drug development company with a proprietary and proven companion diagnostic platform and six cancer products in clinical development. By combining cutting-edge science from genetics and oncology, OV is the first to develop a Drug Response Predictor - DRP®. Using the DRP, our offset is treating the particular genetic characteristics of the individual tumor. Our innovative technology makes us able to track, match and treat the cancer with precision. Our DRP may prolong life ultimately increase survival. OV has HQ in Denmark and sites in Europe, Boston and Arizona.